Catalent price target raised to $63.50 from $56 at Baird

Baird raised the firm’s price target on Catalent to $63.50 from $56 and keeps an Outperform rating on the shares. The firm said Q2 showed a revenue beat, while adjusted EBITDA and EPS missed and noting that overall PCH was solid, but Biologics disappointed, with some kitchen sinking of costs driving lower results in front of buyout.